Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The lead candidate treats the underlying biomechanical cause of LMNA dilated cardiomyopathy, while their PrOSIA mechanobiology platform enables target discovery and validation for additional genetic cardiomyopathies.
Lead Product(s): Recombinant AAV‑based Gene Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2022
Details:
Nuevocor’s lead program is a recombinant adeno-associated virus (AAV)‑based gene therapy for patients suffering from Dilated cardiomyopathy (DCM) due to mutations in the Lamin A/C (LMNA) gene.
Lead Product(s): Recombinant Adeno-associated Virus Based Gene Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2022
Details:
The funds will be used to accelerate the preclinical development of its lead programme, an adeno-associated virus (AAV) – based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the lamin A/C (LMNA) gene.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: EVX Ventures
Deal Size: $24.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 18, 2021